Invitrogen has introduced Lipofectamine LTX, a transfection reagent for DNA delivery.
According to the company, the reagent demonstrates high levels of transfection efficiency and protein expression with more than 90 percent viability for a wide range of cells, including primary neuronal cells and other disease-relevant cell types.